Press Release History - 2015

  • 8 Dec 2015
    Regulated Information - Transparency Statement - Landon and Thomas Clay
  • 1 Dec 2015
    Regulated Information - Transparency Statement, Landon T. Clay
  • 18 Nov 2015
    ThromboGenics Reports Positive 2 Year Results from the OASIS Study with JETREA® (ocriplasmin) for the treatment of Symptomatic VMA/VMT and Macular Hole
  • 13 Nov 2015
    ThromboGenics Presents Full OASIS JETREA Trial Data Analysis (incl ERG) and Further Real World Clinical Data at Upcoming AAO 2015 in Las Vegas
  • 12 Nov 2015
    ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA® for the Treatment of Non-Proliferative Diabetic Retinopathy (CIRCLE)
  • 5 Nov 2015
    ThromboGenics Business Update – Q3 2015
  • 5 Oct 2015
    ThromboGenics presenting new vitreo-retinal research findings at European Association for Vision and Eye Research (EVER) meeting
  • 10 Sep 2015
    Baron Philippe Vlerick increases shareholding in ThromboGenics NV to 6.4%
  • 26 Aug 2015
    ThromboGenics Business Update H1 2015
  • 20 Jul 2015
    Regulated Information - Transparency Statement
  • 26 Jun 2015
    Oncurious NV Appoints Prof Dr Peter Carmeliet as its Chief Scientific Strategy Advisor
  • 20 May 2015
    ThromboGenics Q1 2015 Business Update
  • 19 May 2015
    Transparency Statement - Philippe Baron Vlerick 3.6% shareholding
  • 23 Apr 2015
    ThromboGenics Starts Evaluating JETREA® for the Treatment of Retinal Vein Occlusion (RVO)
  • 21 Apr 2015
    Transparency Statement - Norges Bank 2.98% shareholding
  • 14 Apr 2015
    ThromboGenics and VIB launch New Oncology Company Oncurious NV to develop TB-403 for Pediatric Brain Tumors
  • 3 Apr 2015
    Transparency Statement - Norges Bank 2,95% shareholding
  • 24 Mar 2015
    ThromboGenics Announces Positive Topline Results from OASIS Study
  • 16 Mar 2015
    ThromboGenics’ JETREA® Gains Approval in Brazil
  • 12 Mar 2015
    ThromboGenics Full Year 2014 Business Update
  • 5 Mar 2015
    ThromboGenics Appoints Dr Joseph Markoff as Scientific Advisor
  • 2 Mar 2015
    ThromboGenics Receives Positive CHMP Opinion for Ready Diluted Formulation of JETREA®
  • 12 Feb 2015
    ThromboGenics’ JETREA® Gains Further Approvals
  • 5 Feb 2015
    Thrombogenics Awarded €1.1 million IWT Research Grant
  • 22 Jan 2015
    ThromboGenics Appoints Emmanuèle Attout as Independent Non-Executive Director
  • 22 Jan 2015
    Norges Bank notified 3.03% shareholding in ThromboGenics NV
  • 7 Jan 2015
    ThromboGenics Appoints Dominique Vanfleteren as new Chief Financial Officer